Oruka Therapeutics (ORKA) | Stock Overview & Key Data
Oruka Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $75,932,640.00 on February 14, 2000
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Oruka Therapeutics
ORKA
|
3.40B Mid-cap | -1.36% | -13.93% | 74.18% | 93.24% | 102.33% | 434.03% | 131.16% | 36.62% | -91.76% | -99.68% | -100.00% |
|
Vertex
VRTX
|
109.45B Large-cap | -2.03% | -0.35% | -9.68% | -7.51% | -5.26% | 1.24% | 34.08% | 113.19% | 376.31% | 717.28% | 1,190.86% |
|
Regeneron
REGN
|
80.98B Large-cap | -1.40% | -12.73% | -19.27% | -14.47% | -20.27% | 25.39% | -16.92% | 20.10% | 53.41% | 959.24% | 4,557.42% |
|
Axsome Therapeutics
AXSM
|
9.51B Mid-cap | -0.45% | 4.37% | 42.32% | 57.95% | 30.66% | 122.97% | 216.35% | 282.39% | 2,961.10% | 2,485.23% | 2,485.23% |
|
Praxis Precision
PRAX
|
9.60B Mid-cap | -21.90% | -17.38% | -12.35% | 49.84% | -2.61% | 807.83% | 2,210.03% | 21.08% | -16.07% | -16.07% | -16.07% |
|
Bio-Techne
TECH
|
9.07B Mid-cap | 5.74% | -7.11% | -10.77% | -20.32% | -14.75% | 6.78% | -37.73% | -51.28% | 86.91% | 161.27% | 281.12% |
Ownership & Short Interest
Calculate Your Oruka Therapeutics Investment Returns
Long-Term Investment Performance Analysis
Oruka Therapeutics stock price in May 2016 was $710.64, A $1,000.00 lump sum investment in Oruka Therapeutics made 10 years ago would be worth approximately $80.49 today, representing a negative return of -91.95%. This translates to an annualized return (CAGR) of -22.25%.
10 Years Investment Scenario (May 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ORKA's 52-week high and low?
- In the last 52 weeks, Oruka Therapeutics reached a high of $91.00 (on N/A) and a low of $10.77 (on June 23, 2025).
- What is the market cap and P/E ratio for ORKA?
- Curious about Oruka Therapeutics's size and valuation? Its market capitalization stands at 3.40B. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -26.14.
- Does ORKA pay dividends? If so, what's the yield?
- Yes, Oruka Therapeutics is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 161.33%, and the company has paid an average of $6.45 per share annually over the past 3 years.
- Who are Oruka Therapeutics's main competitors or similar companies to consider before investing?
When looking at Oruka Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology 1.24% 34.08% Regeneron
REGN80.98B Healthcare Biotechnology 25.39% -16.92% Axsome Therapeutics
AXSM9.51B Healthcare Biotechnology 122.97% 216.35% Praxis Precision
PRAX9.60B Healthcare Biotechnology 807.83% 2,210.03% Bio-Techne
TECH9.07B Healthcare Biotechnology 6.78% -37.73% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Oruka Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Oruka Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -24.69%, the Debt to Equity ratio from the most recent quarter is 0.41, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for ORKA?
- Looking at Oruka Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of ORKA stock is held by insiders and institutions?
- Wondering who owns Oruka Therapeutics stock? Company insiders (like executives and directors) hold about 1.64% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 107.37%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.